CANCER IN AFRICA: BRIDGING SCIENCE AND HUMANITY ABSTRACT PUBLICATION
AORTIC INTERNATIONAL CANCER CONFERENCE
CANCER IN AFRICA:
BRIDGING SCIENCE
AND HUMANITY
21 – 24 NOVEMBER 2013
DURBAN, SOUTH AFRICA
ABSTRACT PUBLICATION
Tykerb A4 advert p 23/8/13 2:10 pm Page 1
Composite
C M Y CM MY CY CMY K
ABSTRACT PUBLICATION
This abstract publication contains the abstracts from the AORTIC 2013 Call for Abstracts
which will be given as oral or poster presentations. It also contains abstracts from many of
the Invited Speakers on the topics they will address in workshops and plenary sessions.
Use this programme and poster schedule in conjunction with the abstract publication. If
a presentation in the programme or poster schedule has an abstract, it will be found under
the presenter’s last name in the abstract publication. The abstracts are listed alphabetically
by the corresponding author’s (or presenter’s) last name.
CONFERENCE PROCEEDINGS
All delegates received the conference proceedings in their delegate bag: the conference
handbook and this abstract publication USB flash drive. Both contain the schedule at a
glance, the programme and the poster schedule.
PROGRAMME
Refer to the detailed programme to find out what is happening: who is presenting, what
topic is being presented on, who is chairing the session, what time it is happening, and in
which venue.
POSTER SCHEDULE
Refer to the poster schedule to find out which posters are being presented each day, along
with their corresponding authors, titles and poster numbers. To locate a particular poster
on the day it is being displayed, look for the poster number in the poster schedule then
follow the signage in the poster display to find the poster. The poster display is in Hall 3.
Posters are displayed for one day and change at the beginning of each day, so be sure to
view them daily.
COPYRIGHT
Copyright for the abstracts published in this volume rests with the author/s and any enquiries
should be directed to the corresponding author/s.
CONTENTS
AORTIC 2013|DURBAN|21–24 NOVEMBER 2013
SCHEDULE AT A GLANCE
PRE-CONFERENCE WORKSHOPS | WEDNESDAY, 20 NOVEMBER
07h00 - 17h30 Registraon
09h00 - 10h30 AORTIC-IPOS ACADEMY EMBLEM AND SELECTED
NCI FUNDED RESEARCH
ON BURKITT LYMPHOMA
AORTIC/IUBMB/NCI (USA)
ESOPHAGEAL CANCER
SYMPOSIUM
CANCER ADVOCACY
MASTERS TRAINING
WORKSHOP
(by invitaon)
10h30 - 11h00 Tea Break
11h00 - 13h00 AORTIC-IPOS ACADEMY EMBLEM AND SELECTED
NCI FUNDED RESEARCH
ON BURKITT LYMPHOMA
AORTIC/IUBMB/NCI (USA)
ESOPHAGEAL CANCER
SYMPOSIUM
CANCER ADVOCACY
MASTERS TRAINING
WORKSHOP
(by invitaon)
13h00 - 14h30 Lunch
14h30 - 17h30 AORTIC-IPOS ACADEMY EMBLEM AND SELECTED
NCI FUNDED RESEARCH
ON BURKITT LYMPHOMA
AORTIC/IUBMB/NCI (USA)
ESOPHAGEAL CANCER
SYMPOSIUM
CANCER ADVOCACY
MASTERS TRAINING
WORKSHOP
(by invitaon)
PRE-CONFERENCE WORKSHOPS | THURSDAY, 21 NOVEMBER
07h00 - 17h30 Registraon
09h00 - 10h30 CERVICAL CANCER
PREVENTION I
BEST PRACTICE ON
PROSTATE CANCER
DIAGNOSIS AND
TREATMENT
AORTIC/IUBMB/NCI (USA)
ESOPHAGEAL CANCER
SYMPOSIUM
CANCER ADVOCACY
WORKSHOP AND EXPO
BIG CAT GRANTS I
10h30 - 11h00 Tea Break / Exhibion / Posters
11h00 - 13h00 CERVICAL CANCER
PREVENTION II
CANCER AND SEXUAL
HEALTH
AORTIC/IUBMB/NCI (USA)
ESOPHAGEAL CANCER
SYMPOSIUM
CANCER ADVOCACY
WORKSHOP AND EXPO
THE AFRICAN
PERSPECTIVE ON CANCER
CONTROL AND NCDS
13h00 - 14h30 Lunch / Exhibion / Posters
13h15 - 14h15 CANCER SURVIVORS
FORUM
NCDS AFRICAN OUTCOMES MSD SYMPOSIUM
14h30 - 17h30
4h30 – 17h30
14h30 - 17h30
HPV CERVICAL
CANCER NETWORK IN
FRANCOPHONE AFRICA
THE CASE FOR CANCER
REGISTRIES IN AFRICA
AORTIC/IUBMB/NCI (USA)
ESOPHAGEAL CANCER
SYMPOSIUM
CANCER ADVOCACY
WORKSHOP AND EXPO
MD ANDERSON GLOBAL
INITIATIVE FOR CANCER
CARE IN AFRICA
18h30 - 00h00 OPENING CEREMONY AND WELCOME RECEPTION
DAY ONE | FRIDAY, 22 NOVEMBER
07h00 - 17h30 Registraon
07h00 - 07h50 NIH GRANTS MANAGEMENT TRAINING
PROGRAMME
RADIATION ONCOLOGY
08h00 - 08h30 CAN GLOBAL HEALTH STRATEGIES IMPACT CANCER CONTROL IN AFRICA?
08h30 - 09h00 OVERVIEW OF CANCER IN AFRICA
09h10 - 10h30 PATHOLOGY UROLOGY
10h30 - 11h00 Tea Break / Exhibion / Posters
11h00 - 13h00 PATHOLOGY I PALLIATIVE CARE I NATIONAL CANCER CONTROL
PLANS
BIG CAT GRANTS II FREE COMMUNICATION
OF ABSTRACTS I
13h00 - 14h30 Lunch / Exhibion / Posters
13h15 - 14h15 VARIAN SYMPOSIUM GSK VACCINES SYMPOSIUM
14h30 - 17h30 PATHOLOGY II PALLIATIVE CARE II AFRICAN CANCER REGISTRY
NETWORK
RADIATION AND
CHEMOTHERAPY
FREE COMMUNICATION
OF ABSTRACTS II
18h00 - 20h00 AORTIC GENERAL ASSEMBLY
Schedule at a glance 2
Programme 4
Poster schedule 13
Abstracts 19
Lunch symposia 444
2
2
AORTIC 2013|DURBAN|21–24 NOVEMBER 2013
PLENARY
In patients with HIV and in particular heavily undertreated population with low HAART coverage (or
patients with inadequately suppressed virus) the risk of viral induced lymphomagenesis is primarily
due to HHV8 and EBV. Risk appears to be diminished significantly when CD4 counts are maintained
above 500 cells/uL. This supports the evolving strategy that maintaining high levels of CD4 count
at all times by earlier intervention with HAART. The most common HRL include Burkitt lymphoma
(BL) and diffuse large B-cell lymphoma (DLBCL). Lymphomas occurring specifically in HIV patients
include primary effusion lymphoma (PEL) and its solid variants, lymphoma associated with KSHV-
related multicentric Castleman disease (MCD), and plasmablastic lymphoma. For HIV-infected
patients with B-cell NHL, solid evidence points to the safety and efficacy of combined treatment
including Rituximab, as in the general population. Rituximab based protocols have shown significant
improvement of survival; however caution in the use of Rituximab in patients with CD4 count <
50/µL is advocated. A question is still debated concerning the use of HAART concomitantly or just
after CT, due the potential risk of adverse drug-drug interactions. The optimal therapy for AIDS-BL
is still controversial, although the CHOP backbone is not currently recommended. At this time, it
is reasonable to recommend more intensive protocols for BL patients on effective HAART such as
CODOXAM. Several new treatment strategies including the introduction of proteasome inhibitors,
angiogenesis inhibitors and targeted therapy are been tested. Large cohort clinical trials and high
quality biobanking need to be established to define optimal solutions and define genomic pathways
for potential therapy.
Abayomi, Emmanuel Akinola
MANAGEMENT OF HIV/AIDS-ASSOCIATED NON-HODGKIN’S
LYMPHOMAS: SEPARATING FACT FROM FICTION
Emmanuel Akinola Abayomi*
Stellenbosch University/NHLS, South Africa
Correspondence Abayomi, Emmanuel Akinola
Email: [email protected]
Haematology
09h10–10h30
Saturday
23 November
2013
SCHEDULE AT A GLANCE
PRE-CONFERENCE WORKSHOPS | WEDNESDAY, 20 NOVEMBER
07h00 - 17h30 Registraon
09h00 - 10h30 AORTIC-IPOS ACADEMY EMBLEM AND SELECTED
NCI FUNDED RESEARCH
ON BURKITT LYMPHOMA
AORTIC/IUBMB/NCI (USA)
ESOPHAGEAL CANCER
SYMPOSIUM
CANCER ADVOCACY
MASTERS TRAINING
WORKSHOP
(by invitaon)
10h30 - 11h00 Tea Break
11h00 - 13h00 AORTIC-IPOS ACADEMY EMBLEM AND SELECTED
NCI FUNDED RESEARCH
ON BURKITT LYMPHOMA
AORTIC/IUBMB/NCI (USA)
ESOPHAGEAL CANCER
SYMPOSIUM
CANCER ADVOCACY
MASTERS TRAINING
WORKSHOP
(by invitaon)
13h00 - 14h30 Lunch
14h30 - 17h30 AORTIC-IPOS ACADEMY EMBLEM AND SELECTED
NCI FUNDED RESEARCH
ON BURKITT LYMPHOMA
AORTIC/IUBMB/NCI (USA)
ESOPHAGEAL CANCER
SYMPOSIUM
CANCER ADVOCACY
MASTERS TRAINING
WORKSHOP
(by invitaon)
PRE-CONFERENCE WORKSHOPS | THURSDAY, 21 NOVEMBER
07h00 - 17h30 Registraon
09h00 - 10h30 CERVICAL CANCER
PREVENTION I
BEST PRACTICE ON
PROSTATE CANCER
DIAGNOSIS AND
TREATMENT
AORTIC/IUBMB/NCI (USA)
ESOPHAGEAL CANCER
SYMPOSIUM
CANCER ADVOCACY
WORKSHOP AND EXPO
BIG CAT GRANTS I
10h30 - 11h00 Tea Break / Exhibion / Posters
11h00 - 13h00 CERVICAL CANCER
PREVENTION II
CANCER AND SEXUAL
HEALTH
AORTIC/IUBMB/NCI (USA)
ESOPHAGEAL CANCER
SYMPOSIUM
CANCER ADVOCACY
WORKSHOP AND EXPO
THE AFRICAN
PERSPECTIVE ON CANCER
CONTROL AND NCDS
13h00 - 14h30 Lunch / Exhibion / Posters
13h15 - 14h15 CANCER SURVIVORS
FORUM
NCDS AFRICAN OUTCOMES MSD SYMPOSIUM
14h30 - 17h30
4h30 – 17h30
14h30 - 17h30
HPV CERVICAL
CANCER NETWORK IN
FRANCOPHONE AFRICA
THE CASE FOR CANCER
REGISTRIES IN AFRICA
AORTIC/IUBMB/NCI (USA)
ESOPHAGEAL CANCER
SYMPOSIUM
CANCER ADVOCACY
WORKSHOP AND EXPO
MD ANDERSON GLOBAL
INITIATIVE FOR CANCER
CARE IN AFRICA
18h30 - 00h00 OPENING CEREMONY AND WELCOME RECEPTION
DAY ONE | FRIDAY, 22 NOVEMBER
07h00 - 17h30 Registraon
07h00 - 07h50 NIH GRANTS MANAGEMENT TRAINING
PROGRAMME
RADIATION ONCOLOGY
08h00 - 08h30 CAN GLOBAL HEALTH STRATEGIES IMPACT CANCER CONTROL IN AFRICA?
08h30 - 09h00 OVERVIEW OF CANCER IN AFRICA
09h10 - 10h30 PATHOLOGY UROLOGY
10h30 - 11h00 Tea Break / Exhibion / Posters
11h00 - 13h00 PATHOLOGY I PALLIATIVE CARE I NATIONAL CANCER CONTROL
PLANS
BIG CAT GRANTS II FREE COMMUNICATION
OF ABSTRACTS I
13h00 - 14h30 Lunch / Exhibion / Posters
13h15 - 14h15 VARIAN SYMPOSIUM GSK VACCINES SYMPOSIUM
14h30 - 17h30 PATHOLOGY II PALLIATIVE CARE II AFRICAN CANCER REGISTRY
NETWORK
RADIATION AND
CHEMOTHERAPY
FREE COMMUNICATION
OF ABSTRACTS II
18h00 - 20h00 AORTIC GENERAL ASSEMBLY
3
2
AORTIC 2013|DURBAN|21–24 NOVEMBER 2013
PLENARY
In patients with HIV and in particular heavily undertreated population with low HAART coverage (or
patients with inadequately suppressed virus) the risk of viral induced lymphomagenesis is primarily
due to HHV8 and EBV. Risk appears to be diminished significantly when CD4 counts are maintained
above 500 cells/uL. This supports the evolving strategy that maintaining high levels of CD4 count
at all times by earlier intervention with HAART. The most common HRL include Burkitt lymphoma
(BL) and diffuse large B-cell lymphoma (DLBCL). Lymphomas occurring specifically in HIV patients
include primary effusion lymphoma (PEL) and its solid variants, lymphoma associated with KSHV-
related multicentric Castleman disease (MCD), and plasmablastic lymphoma. For HIV-infected
patients with B-cell NHL, solid evidence points to the safety and efficacy of combined treatment
including Rituximab, as in the general population. Rituximab based protocols have shown significant
improvement of survival; however caution in the use of Rituximab in patients with CD4 count <
50/µL is advocated. A question is still debated concerning the use of HAART concomitantly or just
after CT, due the potential risk of adverse drug-drug interactions. The optimal therapy for AIDS-BL
is still controversial, although the CHOP backbone is not currently recommended. At this time, it
is reasonable to recommend more intensive protocols for BL patients on effective HAART such as
CODOXAM. Several new treatment strategies including the introduction of proteasome inhibitors,
angiogenesis inhibitors and targeted therapy are been tested. Large cohort clinical trials and high
quality biobanking need to be established to define optimal solutions and define genomic pathways
for potential therapy.
Abayomi, Emmanuel Akinola
MANAGEMENT OF HIV/AIDS-ASSOCIATED NON-HODGKIN’S
LYMPHOMAS: SEPARATING FACT FROM FICTION
Emmanuel Akinola Abayomi*
Stellenbosch University/NHLS, South Africa
Correspondence Abayomi, Emmanuel Akinola
Email: [email protected]
Haematology
09h10–10h30
Saturday
23 November
2013
2AORTIC 2013|DURBAN|21–24 NOVEMBER 2013
PLENARY
In patients with HIV and in particular heavily undertreated population with low HAART coverage (or
patients with inadequately suppressed virus) the risk of viral induced lymphomagenesis is primarily
due to HHV8 and EBV. Risk appears to be diminished significantly when CD4 counts are maintained
above 500 cells/uL. This supports the evolving strategy that maintaining high levels of CD4 count
at all times by earlier intervention with HAART. The most common HRL include Burkitt lymphoma
(BL) and diffuse large B-cell lymphoma (DLBCL). Lymphomas occurring specifically in HIV patients
include primary effusion lymphoma (PEL) and its solid variants, lymphoma associated with KSHV-
related multicentric Castleman disease (MCD), and plasmablastic lymphoma. For HIV-infected
patients with B-cell NHL, solid evidence points to the safety and efficacy of combined treatment
including Rituximab, as in the general population. Rituximab based protocols have shown significant
improvement of survival; however caution in the use of Rituximab in patients with CD4 count <
50/µL is advocated. A question is still debated concerning the use of HAART concomitantly or just
after CT, due the potential risk of adverse drug-drug interactions. The optimal therapy for AIDS-BL
is still controversial, although the CHOP backbone is not currently recommended. At this time, it
is reasonable to recommend more intensive protocols for BL patients on effective HAART such as
CODOXAM. Several new treatment strategies including the introduction of proteasome inhibitors,
angiogenesis inhibitors and targeted therapy are been tested. Large cohort clinical trials and high
quality biobanking need to be established to define optimal solutions and define genomic pathways
for potential therapy.
Abayomi, Emmanuel Akinola
MANAGEMENT OF HIV/AIDS-ASSOCIATED NON-HODGKIN’S
LYMPHOMAS: SEPARATING FACT FROM FICTION
Emmanuel Akinola Abayomi*
Stellenbosch University/NHLS, South Africa
Correspondence Abayomi, Emmanuel Akinola
Email: [email protected]
Haematology
09h10–10h30
Saturday
23 November
2013
SCHEDULE AT A GLANCE
DAY TWO | SATURDAY, 23 NOVEMBER
07h00 - 17h30 Registraon
07h00 - 07h50 PSYCHOSOCIAL IMPACT OF CANCER DIAGNOSIS
STATE OF MEDICAL EDUCATION IN AFRICA
08h00 - 08h30 PLACING PATIENTS' HUMANITY AT THE CENTRE OF OUR CARE
08h30 - 09h00 AFRICAN PALLIATIVE CARE AND ITS CONTRIBUTION TO THE WORLD
09h10 - 10h30 BREAST CANCER HAEMATOLOGY
10h30 - 11h00 Tea Break / Exhibion / Posters
11h00 - 13h00 BREAST CANCER I LIVER CANCER TOBACCO-RELATED CANCERS PAIN MANAGEMENT FREE COMMUNICATION
OF ABSTRACTS III
13h00 - 14h30 Lunch / Exhibion / Posters
13h15 - 14h15 ROCHE SYMPOSIUM GSK ONCOLOGY
SYMPOSIUM
GUIDELINES FOR CANCER MANAGEMENT IN AFRICA
14h30 - 17h30 BREAST CANCER II PROSTATE CANCER JOINT AORTIC-ASCO
SYMPOSIUM: CANCER
BIOLOGY
ONCOLOGY NURSING FREE COMMUNICATION
OF ABSTRACTS IV
19h30 - 00h00 GALA DINNER
DAY THREE | SUNDAY, 24 NOVEMBER
07h00 - 14h00 Registraon
07h00 - 07h50 PUBLIC-PRIVATE PARTNERSHIPS VACCINE IMPLEMENTATION
08h00 - 08h30 COMBATING CERVICAL AND BREAST CANCER IN AFRICA
08h30 - 09h00 VIRUSES AND CANCER
09h10 - 10h30 ENVIRONMENT AND OCCUPATION IN CANCER GYNAECOLOGICAL CANCERS
10h30 - 11h00 Tea Break / Exhibion / Posters
11h00 - 13h00 PAEDIATRIC ONCOLOGY AIDS-RELATED
MALIGNANCIES
COLORECTAL CANCER AORTIC'S CONTINENTAL
CANCER CONTROL
PLAN
FREE COMMUNICATION
OF ABSTRACTS V
13h15 - 14h00 CLOSING SESSION
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
1
/
452
100%
